Literature DB >> 6311375

The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor.

R R Martodam, K S Thornton, D A Sica, S M D'Souza, L Flora, G R Mundy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6311375     DOI： 10.1007/bf02405086

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  18 in total

Review 1.  Calcium and cancer.

Authors:  G R Mundy
Journal:  Life Sci       Date:  1978-10-30       Impact factor: 5.037

2.  Creatinine assay by a reaction-kinetic principle.

Authors:  K Larsen
Journal:  Clin Chim Acta       Date:  1972-10       Impact factor: 3.786

3.  Phosphaturia in hypercalcemic breast cancer patients.

Authors:  G C Schussler; M Verso; T Nemoto
Journal:  J Clin Endocrinol Metab       Date:  1972-10       Impact factor: 5.958

4.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

5.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors:  R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal:  N Engl J Med       Date:  1973-12-27       Impact factor: 91.245

6.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.

Authors:  E S Siris; W H Sherman; D C Baquiran; J P Schlatterer; E F Osserman; R E Canfield
Journal:  N Engl J Med       Date:  1980-02-07       Impact factor: 91.245

7.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

8.  Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism.

Authors:  E Shane; D C Baquiran; J P Bilezikian
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

9.  Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo.

Authors:  H Fleisch; R G Russell; M D Francis
Journal:  Science       Date:  1969-09-19       Impact factor: 47.728

10.  Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.

Authors:  T P Jacobs; E S Siris; J P Bilezikian; D C Baquiran; E Shane; R E Canfield
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391
View more
  12 in total

Review 1.  [Introduction to bisphosphonates. History and functional mechanisms].

Authors:  H Fleisch
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  The Walker 256/B carcinosarcoma in thyroparathyroidectomized rats: a model to evaluate inhibitors of bone resorption.

Authors:  R Rizzoli; H Fleisch
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

4.  Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.

Authors:  S Hirschel-Scholz; J Caverzasio; R Rizzoli; J P Bonjour
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 5.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 6.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.

Authors:  M Yamamoto; A Markatos; J G Seedor; P Masarachia; M Gentile; G A Rodan; R Balena
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

8.  Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone.

Authors:  P J Kostenuik; G Singh; K L Suyama; F W Orr
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

9.  The effects of thionapthene-2-carboxylic acid-lysine on the hypercalcemia of malignancy in the rat.

Authors:  J E Decker; N E Morrison; J A Lorenzo; C M Samour; B A McCarron; L G Raisz
Journal:  Calcif Tissue Int       Date:  1989-01       Impact factor: 4.333

Review 10.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.